nach oben

Erschienen in:

23.01.2020 | Clinical Study

Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients

verfasst von: Bruno Carvalho, Rafaela Gonçalves Lopes, Paulo Linhares, Andreia Costa, Cláudia Caeiro, Ana Catarina Fernandes, Nuno Tavares, Lígia Osório, Rui Vaz

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Arterial hypertension and proteinuria are common side effects of antiangiogenic treatment and might represent a biomarker of response in patients with glioblastoma. The aim of this study was to assess the impact of these side effects in predicting therapeutic response to second line chemotherapy with bevacizumab.

Methods

We evaluated clinical and survival data of glioblastoma patients who underwent treatment with bevacizumab after progression under temozolomide, at CHUSJ between 2010 and 2017. We analysed treatment-related arterial hypertension, proteinuria grade, thrombotic and haemorrhagic events during treatment. Overall survival (OS) and progression free survival (PFS) under bevacizumab were calculated according to the Kaplan–Meier method. Multivariate analysis was performed using Cox proportional hazards method.

Results

We evaluated 140 patients. Arterial hypertension and proteinuria occurred in 23 (16.3%) and 17 (12.1%) patients, respectively. PFS during treatment with bevacizumab was 12 months (95% CI 7.9–16.1) in the hypertensive group and 4 months (95% CI 3.2–4.8) in the normotensive group (p = 0.005). Patients with proteinuria had a PFS of 10 months (95% CI 4.9–15.0) versus 4 months (95% CI 3.4–4.8) in patients without proteinuria (p = 0.002). Multivariate analysis revealed hypertension and proteinuria as independent prognostic factors of PFS and OS.

Conclusion

Our data suggest that hypertension and proteinuria can be effective predictors of response to antiangiogenic therapy in recurrent glioblastoma and are associated with longer disease control.

Darefsky AS, King JT Jr, Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer 118(8):2163–2172. https://doi.org/10.1002/cncr.26494 CrossRefPubMed

Stupp RJNEJM (2005) European Organisation for Research and Treatment of Cancer brain tumor and radiotherapy groups; National Cancer Institute of Canada clinical trials group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma 352:987–996

Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14(11):1131–1138. https://doi.org/10.1634/theoncologist.2009-0121 CrossRefPubMed

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740. https://doi.org/10.1200/JCO.2008.19.8721 CrossRefPubMed

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722. https://doi.org/10.1056/NEJMoa1308345 CrossRefPubMed

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708. https://doi.org/10.1056/NEJMoa1308573 CrossRefPubMedPubMedCentral

Khoja Leila, Kumaran G, Zee YK, Murukesh Nishanth, Swindell Ric, Saunders MP, Clamp AR, Valle JW, Jayson GWGC, Hasan J (2014) Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer. J Clin Gastroenterol 48:4CrossRef

Lombardi G, Zustovich F, Farina P, Fiduccia P, Della Puppa A, Polo V, Bertorelle R, Gardiman MP, Banzato A, Ciccarino P, Denaro L, Zagonel V (2013) Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature. Anticancer Drugs 24(1):90–97. https://doi.org/10.1097/CAD.0b013e32835aa5fd CrossRefPubMed

Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P (2011) Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 104(4):599–604. https://doi.org/10.1038/bjc.2011.2 CrossRefPubMedPubMedCentral

10.

Zhong J, Ali AN, Voloschin AD, Liu Y, Curran WJ Jr, Crocker IR, Shu HK (2015) Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab. Cancer 121(9):1456–1462. https://doi.org/10.1002/cncr.29234 CrossRefPubMed

11.

Institute NC (2017) Common terminology criteria for adverse events, version 5.0. 28/03/2019 edn. National Cancer Institute, National Institutes of Health, Department of Health and Human Services

12.

Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6(6):327CrossRef

13.

Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, Durand JP, Treluyer JM, Knebelmann B, Goldwasser F (2011) An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist 16(9):1325–1332. https://doi.org/10.1634/theoncologist.2010-0002 CrossRefPubMedPubMedCentral

14.

Gampenrieder SP, Romeder F, Muss C, Pircher M, Ressler S, Rinnerthaler G, Bartsch R, Sattlberger C, Mlineritsch B, Greil R (2014) Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis. Anticancer Res 34(1):227–233PubMed

15.

Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20(2):227–230. https://doi.org/10.1093/annonc/mdn637 CrossRefPubMed

16.

Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377(20):1954–1963. https://doi.org/10.1056/NEJMoa1707358 CrossRefPubMed

17.

Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28(17):2817–2823. https://doi.org/10.1200/JCO.2009.26.3988 CrossRefPubMedPubMedCentral

18.

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745. https://doi.org/10.1200/JCO.2008.16.3055 CrossRefPubMed

19.

Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE 2nd, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS (2011) Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 101(1):57–66. https://doi.org/10.1007/s11060-010-0217-6 CrossRefPubMed

20.

Wick A, Schafer N, Dorner N, Schemmer D, Platten M, Bendszus M, Wick W (2010) Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome. J Neurooncol 97(1):157–158. https://doi.org/10.1007/s11060-009-0003-5 CrossRefPubMed

21.

Nangia CS, Wang D, Scarpace L, Schultz L, Khanshour A, Mikkelsen T (2011) The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme. J Clin Oncol. https://doi.org/10.1200/jco.2011.29.15_suppl.2021 CrossRef

22.

Mourad JJ, des Guetz G, Debbabi H, Levy BI (2008) Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 19(5):927–934. https://doi.org/10.1093/annonc/mdm550 CrossRefPubMed

23.

Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15(9):943–953. https://doi.org/10.1016/S1470-2045(14)70314-6 CrossRefPubMed

Titel: Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients
verfasst von: Bruno Carvalho
Rafaela Gonçalves Lopes
Paulo Linhares
Andreia Costa
Cláudia Caeiro
Ana Catarina Fernandes
Nuno Tavares
Lígia Osório
Rui Vaz
Publikationsdatum: 23.01.2020
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03404-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients